Alden Global Capital’s Novavax NVAX Stock Holding History

Alden Global Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-32,025	Closed	-$807K	–	9
2016 Q4	$807K	Buy	+32,025	New	+$934K	0.28%	12
2016 Q3	–	Sell	-30,000	Closed	-$4.36M	–	13
2016 Q2	$4.36M	Sell	30,000 -20,000	-40%	-$2.29M	3.76%	6
2016 Q1	$5.16M	Buy	+50,000	New	+$5.36M	2.08%	13
2015 Q3	–	Sell	-14,750	Closed	-$3.29M	–	25
2015 Q2	$3.29M	Buy	+14,750	New	+$2.59M	3.67%	8

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Alden Global Capital's NVAX Position: Q1 2017 in Review

Alden Global Capital sold out of Novavax (NVAX) in Q1 2017, closing a stake of 32,025 shares — an estimated $807K sold.

Alden Global Capital first reported a position in NVAX in Q2 2015 and held it in 4 quarters. The position peaked at $5.16M in Q1 2016. 129 funds tracked by Wall St. Rank hold NVAX as of Q1 2017.

Alden Global Capital reported no remaining Novavax position as of Q1 2017 after selling out during the quarter.
Alden Global Capital sold 32,025 Novavax shares in Q1 2017, an estimated $807K.
Alden Global Capital first reported a position in Novavax in Q2 2015 and held it in 4 quarters.
Alden Global Capital's Novavax position peaked at $5.16M in Q1 2016.
129 funds tracked by Wall St. Rank held Novavax as of Q1 2017.

Based on Alden Global Capital's 13F filing for Q1 2017, filed 11 May 2017.